Barrett’s esophagus: Review of natural history and comparative efficacy of endoscopic and surgical therapies

Table 4 Efficacy of endoscopic eradication therapy for Barrett’s esophagus with high-grade dysplasia

Ref.	Type1	n	CE-IM	CE-D	NNT to prevent disease progression	Annual disease progression, treatment vs placebo (P value)
Overholt et al[52]	RCT (PDT)	208	52%	77% (including HGD)	22	3.6% vs 8.14% (P = 0.006)
Ganz et al[102]	Retrospective	92	54%	80%	NA	1.4%
Wani et al[22]	Meta-analysis	236	-	-	20.4	1.7% vs 6.6% (P = 0.02)
Shaheen et al[42]	RCT	63	73.8%	81%	6	2.4% vs 19% (P = 0.04)
Shaheen et al[91]	Retrospective	54	89%	93%	NA	0.6%
Moss et al[85]	Prospective (SRER)	35	94%	94%	NA	Nil
Zehetner et al[96]	Retrospective	22	89%	89.5%	NA	Nil
Okoro et al[103]	Retrospective	35	51.2%	79%	NA	2.3% (2 yr)
Bulsiewicz et al[92]	Retrospective	118	90%	97%	NA	NA
Haidry et al[104]	Retrospective	122	85%	92%	NA	2.5% (3 yr)
Li et al[105]	Retrospective	832	83.4%	92.1%	NA	3% (2.8 yr)

¹Studies used endoscopic mucosal resection and radiofrequency ablation unless otherwise stated.

CE-D/IM: Complete eradication of dysplasia/intestinal metaplasia; EAC: Esophageal adenocarcinoma; NNT: Number needed to treat; PDT: Photodynamic therapy; SRER: Stepwise radical endoscopic resection; NA: Not application.